Innodem and Novartis to Test Eye-tracking Technology & Managing Certain MS Accidents

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how Innodem and Novartis Canada are launching a clinical trial to evaluate biomarker eye-tracking technology for monitoring MS progression.

Plus, Price reads “My Coffee Cup Runneth Over, Plus a Darned Interruption”, a column by John Connor.

===================================

Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================

To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/